Dietary phytosterols reduce cyclosporine-induced hypercholesterolemia in apolipoprotein E-knockout mice

Transplantation

Volumn 81, Issue 2, 2006, Pages 207-213

  Moghadasian, Mohammed H ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NONE   (Canada)

Author keywords

Apolipoprotein E knockout mice; Atherosclerosis; Cyclosporine; Lipoproteins; Phytosterols

Indexed keywords

APOLIPOPROTEIN E; BRASSICASTEROL; CAMPESTEROL; CYCLOSPORIN; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; SITOSTEROL; STIGMASTEROL; TRIACYLGLYCEROL; IMMUNOSUPPRESSIVE AGENT; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KNOCKOUT MOUSE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DIET; GENETICS; HUMAN; MOUSE MUTANT; PATHOLOGY; TRANSPLANTATION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BODY WEIGHT; CYCLOSPORINE; DIET; HUMANS; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE AGENTS; LIPIDS; MALE; MICE; MICE, KNOCKOUT; PHYTOSTEROLS; TRANSPLANTS;

EID: 33644866386     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000188177.21406.97     Document Type: Article

References (40)

1. Moghadasian MH, Frohlich JJ. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence. Am J Med 1999; 107(6): 588.
2. Richelle M, Enslen M, Hager C, et al. Both free and esterified plant sterols reduce cholesterol absorption and the bioavailability of beta-carotene and alpha-tocopherol in normocholesterolemic humans. Am J Clin Nutr 2004; 80(1): 171.
3. Berber I, Aydin C, Yigit B, et al. Blood pressure and graft outcome in renal transplantation. Transplant Proc 2005; 37(2): 997.
4. Akhlaghi F, Jackson CH, Parameshwar J, et al. Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation 2002; 73(8): 1258.
5. Baran DA, Galin ID, Gass AL. Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment. Am J Cardiovasc Drugs 2004; 4(1): 21.
6. Busauschina A, Schnuelle P, van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc 2004; 36(2 Suppl): 229S.
7. Oriji GK, Keiser HR. Nitric oxide in cyclosporine A-induced hypertension: role of protein kinase C. Am J Hypertens 1999; 12(11 Pt 1): 1091.
8. Roullet JB, Xue H, McCarron DA, et al. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest 1994; 93(5): 2244.
9. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262(1): 53.
10. Luke DR, Beck JE, Vadiei K, et al. Longitudinal study of cyclosporine and lipids in patients undergoing bone marrow transplantation. J Clin Pharmacol 1990; 30(2): 163.
11. Fernandez-Miranda C, Sanz M, dela Calle A, et al. Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation. Transpl Int 2002; 15(11): 556.
12. Matsumoto Y, Hof A, Baumlin Y, Hof RP. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice. Transplantation 2003; 76(8): 1166.
13. Deters M, Kirchner G, Koal T, et al. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig Dis Sci 2004; 49(1): 30.
14. Vaziri ND, Liang K, Azad H. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. J Pharmacol Exp Ther 2000; 294(2): 778.
15. Wu J, Zhu YH, Patel SB. Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2. Am J Physiol 1999; 277(6 Pt 1): E1087.
16. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, et al. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005; 37(2): 1033.
17. Vorlat A, Conraads VM, Vrints CJ. Regular use of margarine-containing stanol/sterol esters reduces total and low-density lipoprotein (LDL) cholesterol and allows reduction of statin therapy after cardiac transplantation: preliminary observations. J Heart Lung Transplant 2003; 22(9): 1059.
18. Moghadasian MH, McManus BM, Pritchard PH, Frohlich JJ. "Tall oil"-derived phytosterols reduce atherosclerosis in Apo E-deficient mice. Arteriosder Thromb Vasc Biol 1997; 17(1): 119.
19. Moghadasian MH, McManus BM, Godin DV, et al. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation 1999; 99(13): 1733.
20. Hwang MW, Matsumori A, Furukawa Y, et al. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation 1999; 100(12): 1322.
21. Moghadasian MH, McManus BM, Nguyen LB, et al. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans. FASEB J 2001; 15(14): 2623.
22. Turchin A, Wiebe DA, Seely EW, et al. Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant 2005; 35(1): 85.
23. Abbott KC, Koff J, Bohen EM, et al. Maintenance immunosuppression use and the associated risk of avascular necrosis after kidney transplantation in the United States. Transplantation 2005; 79(3): 330.
24. Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004; 18(5): 596.
25. Akhlaghi F, McLachlan AJ, Keogh AM, Brown KF. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997; 44(6): 537.
26. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65(3): 410.
27. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62(3): 311.
28. Fehrman-Ekholm I, Jogestrand T, Angelin B. Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation. Nephron 1996; 72(3): 483.
29. Boissonnat P, Salen P, Guidollet J, et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 1994; 58(2): 245.
30. Pflugfelder PW, Huff M, Oskalns R, et al. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995; 14(4): 613.
31. Le Beller C, Bezie Y, Chabatte C, et al. Co-administration of orlistat and cyclosporine in a heart transplant recipient. Transplantation 2000; 70(10): 1541.
32. Sugimoto K, Sakamoto K, Fujimura A. Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats. Life Sci 1997; 60(3): 173.
33. Gallego C, Sanchez P, Planells C, et al. Interaction between probucol and cyclosporine in renal transplant patients. Ann Pharmacother 1994; 28(7-8): 940.
34. Homan van der Heide JJ, Bilo HJ, Donker AJ, et al. Dietary supplementation with fish oil modifies renal reserve filtration capacity in postoperative, cyclosporin A-treated renal transplant recipients. Transpl Int 1990; 3(3): 171.
35. van der Heide JJ, Bilo HJ, Donker JM, et al. Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 1993; 329(11): 769.
36. Homan van der Heide JJ, Bilo HJ, Donker AJ, et al. The effects of dietary supplementation with fish oil on renal function and the course of early postoperative rejection episodes in cyclosporine-treated renal transplant recipients. Transplantation 1992; 54(2): 257.
37. Rogers TS, Elzinga L, Bennett WM, Kelley VE. Selective enhancement of thromboxane in macrophages and kidneys in cyclosporine-induced nephrotoxicity. Dietary protection by fish oil. Transplantation 1988; 45(1): 153.
38. Elzinga L, Kelley VE, Houghton DC, Bennett WM. Fish oil vehicle for cyclosporine lowers renal thromboxanes and reduces experimental nephrotoxicity. Transplant Proc 1987; 19(1 Pt 2): 1403.
39. Sarris GE, Mitchell RS, Billingham ME, et al. Inhibition of accelerated cardiac allograft arteriosclerosis by fish oil. J Thorac Cardiovasc Surg 1989; 97(6): 841.
40. Alexander JW, Valente JF, Greenberg NA, et al. Dietary omega-3 and omega-9 fatty acids uniquely enhance allograft survival in cyclosporine-treated and donor-specific transfusion-treated rats. Transplantation 1998; 65(10): 1304.